Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of MN-08 in pulmonary arterial hypertension
ChiCTR2100053623Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nitronaphthazine in pulmonary arterial hypertension (PAH), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Primary endpoints: Acute hemodynamics of a single dose and Multiple dosing randomized double-blind placebo-controlled parallel study. Started Dec 2021; status: recruiting.
02
Drugs
nitronaphthazine
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on ChiCTR2100053623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053623.